These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38171649)

  • 21. Safety of sugammadex for reversal of neuromuscular block.
    Honing G; Martini CH; Bom A; van Velzen M; Niesters M; Aarts L; Dahan A; Boon M
    Expert Opin Drug Saf; 2019 Oct; 18(10):883-891. PubMed ID: 31359807
    [No Abstract]   [Full Text] [Related]  

  • 22. Preparing for the unexpected: special considerations and complications after sugammadex administration.
    Iwasaki H; Renew JR; Kunisawa T; Brull SJ
    BMC Anesthesiol; 2017 Oct; 17(1):140. PubMed ID: 29041919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful management of rocuronium-induced anaphylaxis with sugammadex: A case report.
    Hung SK; Yeh CC; Ting PC; Chen CH; Kao MC
    J Int Med Res; 2022 Jul; 50(7):3000605221113913. PubMed ID: 35869623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The future of neuromuscular blocking agents.
    Stäuble CG; Blobner M
    Curr Opin Anaesthesiol; 2020 Aug; 33(4):490-498. PubMed ID: 32628397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does the pretreatment of magnesium sulphate affect the sugammadex reversal time for rocuronium-induced neuromuscular blockade? A meta-analysis.
    Miao M; Zhang J
    J Clin Anesth; 2020 Mar; 60():78-79. PubMed ID: 31476625
    [No Abstract]   [Full Text] [Related]  

  • 26. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.
    Sacan O; White PF; Tufanogullari B; Klein K
    Anesth Analg; 2007 Mar; 104(3):569-74. PubMed ID: 17312210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sugammadex: another milestone in clinical neuromuscular pharmacology.
    Naguib M
    Anesth Analg; 2007 Mar; 104(3):575-81. PubMed ID: 17312211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Sugammadex, a novel drug for neuromuscular blockade reversal].
    Fernández Meré LA; Alvarez-Blanco M
    Rev Esp Anestesiol Reanim; 2010 Feb; 57(2):95-102. PubMed ID: 20337001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of sugammadex and pyridostigmine bromide for reversal of rocuronium-induced neuromuscular blockade in short-term pediatric surgery: A prospective randomized study.
    An J; Lee JH; Kim E; Woo K; Kim H; Lee D
    Medicine (Baltimore); 2020 Feb; 99(7):e19130. PubMed ID: 32049831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block.
    Groudine SB; Soto R; Lien C; Drover D; Roberts K
    Anesth Analg; 2007 Mar; 104(3):555-62. PubMed ID: 17312208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sugammadex to Reverse Neuromuscular Blockade Prior to Withdrawal of Life Support.
    Lemus R; Guider W; Gee SW; Humphrey L; Tobias JD
    J Pain Symptom Manage; 2021 Aug; 62(2):438-442. PubMed ID: 33677073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetic-pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade.
    Kleijn HJ; Zollinger DP; van den Heuvel MW; Kerbusch T
    Br J Clin Pharmacol; 2011 Sep; 72(3):415-33. PubMed ID: 21535448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies.
    Herring WJ; Woo T; Assaid CA; Lupinacci RJ; Lemmens HJ; Blobner M; Khuenl-Brady KS
    J Clin Anesth; 2017 Sep; 41():84-91. PubMed ID: 28802619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sugammadex for reversal of rocuronium-induced neuromuscular blockade in pediatric patients: A systematic review and meta-analysis.
    Won YJ; Lim BG; Lee DK; Kim H; Kong MH; Lee IO
    Medicine (Baltimore); 2016 Aug; 95(34):e4678. PubMed ID: 27559972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia.
    Duvaldestin P; Kuizenga K; Saldien V; Claudius C; Servin F; Klein J; Debaene B; Heeringa M
    Anesth Analg; 2010 Jan; 110(1):74-82. PubMed ID: 19933538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Jones RK; Caldwell JE; Brull SJ; Soto RG
    Anesthesiology; 2008 Nov; 109(5):816-24. PubMed ID: 18946293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sugammadex: Pharmacometrics, Clinical Utility, and Adverse Effects.
    Swerdlow B; Osborne-Smith L
    AANA J; 2022 Apr; 90(2):133-140. PubMed ID: 35343895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rocuronium-induced neuromuscular block and sugammadex in pediatric patient with duchenne muscular dystrophy: A case Report.
    Kim JE; Chun HR
    Medicine (Baltimore); 2017 Mar; 96(13):e6456. PubMed ID: 28353578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sugammadex: A Review of Neuromuscular Blockade Reversal.
    Keating GM
    Drugs; 2016 Jul; 76(10):1041-52. PubMed ID: 27324403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversal of rocuronium induced neuromuscular block with sugammadex in patients under 2 years of age. A series of 280 cases.
    Ozmete O; Dardag E; Civi S
    Ann Ital Chir; 2023; 94():612-616. PubMed ID: 38131376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.